Production (Stage)
Orchestra BioMed Holdings, Inc.
OBIO
$2.72
-$0.01-0.37%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -28.41% | -24.23% | -25.26% | -29.19% | -33.04% |
Total Depreciation and Amortization | 9.31% | 7.32% | 3.86% | 8.58% | 18.37% |
Total Amortization of Deferred Charges | 1.32% | -72.32% | -97.93% | -73.10% | -47.22% |
Total Other Non-Cash Items | 64.98% | 84.58% | 84.82% | 73.23% | 52.41% |
Change in Net Operating Assets | 110.90% | 76.87% | 115.56% | 150.63% | 84.25% |
Cash from Operations | -20.51% | -9.61% | -9.33% | -9.07% | -16.99% |
Capital Expenditure | -670.59% | -270.51% | -33.33% | 61.47% | 91.19% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -64.71% | 29.87% | 158.54% | 163.36% | 156.18% |
Cash from Investing | -66.33% | 22.48% | 158.24% | 163.01% | 155.83% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -99.21% |
Issuance of Common Stock | 5,780.46% | 5,913.78% | 15,124.75% | -99.69% | -99.76% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -100.98% | -100.00% | -100.00% | -100.00% |
Cash from Financing | 372.54% | -36.88% | -91.26% | -121.30% | -107.82% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -207.50% | -177.01% | 108.38% | 108.07% | 143.52% |